CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia-A case report.

Ruth M UrbantatValentin PopperElisabeth MenschelMichael PfeilstöckerErnst ForjanAlexander NaderCatherine R SieghartFelix KeilElisabeth Koller

Published in: Clinical case reports (2021)

CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Keyphrases

acute myeloid leukemia
early onset
drug induced
combination therapy